Clinico-biological features and prognostic significance of PML/RARα isoforms in adult patients with acute promyelocytic leukemia treated with all trans retinoic acid (ATRA) and chemotherapy

Leukemia and Lymphoma

Volumn 45, Issue 3, 2004, Pages 469-480

  Gupta, Vikas K ^a   Yi, Qi Long ^a   Brandwein, Joseph ^a   Chun, Kathy ^b   Lipton, Jeffrey H ^a   Messner, Hans ^a   Schuh, Andre C ^a   Wells, Richard A ^a   Minden, Mark D ^a   Kamel Reid, Suzanne ^a  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY HEALTH NETWORK   (Canada)

Author keywords

Acute promyelocytic leukemia; Isoforms; PML RAR ; Prognosis; Risk stratification

Indexed keywords

AMSACRINE; ANTHRACYCLINE; ANTINEOPLASTIC AGENT; CYTARABINE; DAUNORUBICIN; ETOPOSIDE; GEMTUZUMAB OZOGAMICIN; HARRINGTONINE; IDARUBICIN; ISOPROTEIN; METHOTREXATE; MITOXANTRONE; PREDNISONE; PROMYELOCYTIC LEUKEMIA PROTEIN; RETINOIC ACID; VINCRISTINE;

ADOLESCENT; ADULT; ARTICLE; AUTOLOGOUS BONE MARROW TRANSPLANTATION; CANADA; CLINICAL ARTICLE; CLINICAL FEATURE; CLINICAL PROTOCOL; CONGESTIVE CARDIOMYOPATHY; CONTROLLED STUDY; DISEASE COURSE; DRUG MEGADOSE; EXON; FEMALE; GENOMICS; HIGH RISK PATIENT; HUMAN; INTRON; LEUKOCYTE COUNT; MALE; MYELODYSPLASTIC SYNDROME; PRIORITY JOURNAL; PROGNOSIS; PROMYELOCYTIC LEUKEMIA; RECURRENCE RISK; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STATISTICAL SIGNIFICANCE; SURVIVAL RATE; TUMOR REGRESSION;

ADOLESCENT; ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE MARROW; FEMALE; HUMANS; LEUKEMIA, PROMYELOCYTIC, ACUTE; MALE; MIDDLE AGED; MOLECULAR DIAGNOSTIC TECHNIQUES; NEOPLASM PROTEINS; ONCOGENE PROTEINS, FUSION; PROGNOSIS; PROTEIN ISOFORMS; REMISSION INDUCTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, NEOPLASM; SURVIVAL ANALYSIS; TREATMENT OUTCOME; TRETINOIN;

EID: 10744220143     PISSN: 10428194     EISSN: None     Source Type: Journal    
DOI: 10.1080/10428190310001617295     Document Type: Article

References (34)

1. Larson, R.A., Kondo, K., Vardiman, JW., Butler, A.E., Golomb, H.M. and Rowley, J.D. (1984) "Evidence for a 15;17 translocation in every patient with acute promyelocytic leukemia". Am. J. Med., 76, 827- 841.
2. de The, H., Chomienne, C., Lanotte, M., Degos, L. and Dejean, A. (1990) "The t(15;17) translocation of acute promyelocytic leukaemia fuses the retinoic acid receptor alpha gene to a novel transcribed locus". Nature, 347, 558-561.
3. Kakizuka, A., Miller, W.H., Jr., Umesono, K., Warrell, R.P., Jr., Frankel, S.R., Murty, V.V., et al. (1991) "Chromosomal translocation t(15;17) in human acute promyelocytic leukemia fuses RAR alpha with a novel putative transcription factor, PML". Cell, 66, 663-674.
4. Grignani, F., Ferrucci, P.F., Testa, U., Talamo, G., Fagioli, M., Alcalay, M., et al. (1993) "The acute promyelocytic leukemia-specific PML-RAR alpha fusion protein inhibits differentiation and promotes survival of myeloid precursor cells". Cell, 74, 423-431.
5. Rousselot, P., Hardas, B., Patel, A., Guidez, F., Gaken, J., Castaigne, S., et al. (1994) "The PML-RAR alpha gene product of the t(15;17) translocation inhibits retinoic acid-induced granulocytic differentiation and mediated transactivation in human myeloid cells". Oncogene, 9, 545-551.
6. Pandolfi, P.P., Alcalay, M., Fagioli, M., Zangrilli, D., Mencarelli, A., Diverio, D., et al. (1992) "Genomic variability and alternative splicing generate multiple PML/RAR alpha transcripts that encode aberrant PML proteins and PML/RAR alpha isoforms in acute promyelocytic leukaemia". EMBO J., 11, 1397-1407.
7. Fukutani, H., Naoe, T., Yoshida, H., Yamamori, S. and Ohno, R. (1993) Molecular heterogeneity of the PML gene rearrangement in acute promyelocytic leukemia: prevalence and clinical significance. Jpn. J. Cancer Res., 84, 257-264.
8. Yoshida, H., Naoe, T., Fukutani, H., Kiyoi, H., Kubo, K. and Ohno, R. (1995) "Analysis of the joining sequences of the t(15;17) translocation in human acute promyelocytic leukemia: sequence non-specific recombination between the PML and RARA genes within identical short stretches". Genes Chromosomes Cancer, 12, 37-44.
9. Biondi, A., Rambaldi, A., Pandolfi, P.P., Rossi, V., Giudici, G., Alcalay, M., et al. (1992) "Molecular monitoring of the myl/retinoic acid receptor-alpha fusion gene in acute promyelocytic leukemia by polymerase chain reaction". Blood, 80, 492-497.
10. Gallagher, R.E., Willman, C.L., Slack, J.L., Andersen, J.W., Li, Y.P., Viswanatha, D., et al. (1997) "Association of PML-RAR alpha fusion mRNA type with pretreatment hematologic characteristics but not treatment outcome in acute promyelocytic leukemia: an intergroup molecular study" Blood, 90, 1656-1663.
11. Huang, W., Sun, G.L., Li, X.S., Cao, Q., Lu, Y., Jang, G.S., et al. (1993) "Acute promyelocytic leukemia: clinical relevance of two major PML-RAR alpha isoforms and detection of minimal residual disease by retrotranscriptase/polymerase chain reaction to predict relapse". Blood, 82, 1264-1269.
12. Vahdat, L., Maslak, P., Miller, W.H., Jr., Eardley, A., Heller, G., Scheinberg, D.A. et al. (1994) "Early mortality and the retinoic acid syndrome in acute promyelocytic leukemia: impact of leukocytosis, low-dose chemotherapy, PMN/RAR-alpha isoform, and CD13 expression in patients treated with all-trans retinoic acid". Blood, 84, 3843-3849.
13. Jurcic, J.G., Nimer, S.D., Scheinberg, D.A., DeBlasio, T., Warrell, R.P., Jr. and Miller, W.H., Jr. (2001) "Prognostic significance of minimal residual disease detection and PML/RAR-alpha isoform type: long-term follow-up in acute promyelocytic leukemia". Blood, 98, 2651-2656.
14. Kaplan, E. and Meier, P. (1958) "Nonparametric estimation from incomplete observations". J. Am. Stat. Assoc., 53, 457-481.
15. Gonzalez, M., Barragan, E., Bolufer, P., Chillon, C., Colomer, D., Borstein, R., et al. (2001) "Pretreatment characteristics and clinical outcome of acute promyelocytic leukaemia patients according to the PML-RAR alpha isoforms: a study of the PETHEMA group". Br. J. Haematol., 114, 99-103.
16. Mandelli, F., Diverio, D., Avvisati, G., Luciano, A., Barbui, T., Bernasconi, C., et al. (1997) "Molecular remission in PML/RAR alpha-positive acute promyelocytic leukemia by combined all-trans retinoic acid and idarubicin (AIDA) therapy. Gruppo Italiano-Malattie Ematologiche Maligne dell'Adulto and Associazione Italiana di Ematologia ed Oncologia Pediatrica Cooperative Groups". Blood, 90, 1014-1021.
17. Fenaux, P., Chastang, C., Chevret, S., Sanz, M., Dombret, H., Archimbaud, E., et al. (1999) "A randomized comparison of all transretinoic acid (ATRA) followed by chemotherapy and ATRA plus chemotherapy and the role of maintenance therapy in newly diagnosed acute promyelocytic leukemia. The European APL Group". Blood, 94, 1192-1200.
18. Warrell, R.P., Jr., Maslak, P., Eardley, A., Heller, G., Miller, W.H., Jr. and Frankel, S.R. (1994) "Treatment of acute promyelocytic leukemia with all-trans retinoic acid: an update of the New York experience". Leukemia, 8, 929-933.
19. Asou, N., Adachi, K., Tamura, J., Kanamaru, A., Kageyama, S., Hiraoka, A., et al. (1998) "Analysis of prognostic factors in newly diagnosed acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy. Japan Adult Leukemia Study Group". J. Clin. Oncol., 16, 78-85.
20. Burnett, A.K., Grimwade, D., Solomon, E., Wheatley, K. and Goldstone, A.H. (1999) "Presenting white blood cell count and kinetics of molecular remission predict prognosis in acute promyelocytic leukemia treated with all-trans retinoic acid: result of the Randomized MRC Trial". Blood, 93, 4131-4143.
21. Chou, W.C., Tang, J.L., Yao, M., Liang, Y.J., Lee, F.Y, Lin, M.T., et al. (1997) "Clinical and biological characteristics of acute promyelocytic leukemia in Taiwan: a high relapse rate in patients with high initial and peak white blood cell counts during all-trans retinoic acid treatment". Leukemia, 11, 921-928.
22. Sanz, M.A., Lo Coco, F., Martin, G., Avvisati, G., Rayon, C., Barbui, T., et al. (2000) "Definition of relapse risk and role of nonanthracycline drugs for consolidation in patients with acute promyelocytic leukemia: a joint study of the PETHEMA and GIMEMA cooperative groups". Blood, 96, 1247-1253.
23. Jurcic, J.G., DeBlasio, T., Dumont, L., Yao, T.J. and Scheinberg, D.A. (2000) "Molecular remission induction with retinoic acid and anti-CD33 monoclonal antibody HuM195 in acute promyelocytic leukemia". Clin. Cancer Res., 6, 372-380.
24. Fukutani, H., Naoe, T., Ohno, R., Yoshida, H., Miyawaki, S., Shimazaki, C., et al. (1995) "Isoforms of PML-retinoic acid receptor alpha fused transcripts affect neither clinical features of acute promyelocytic leukemia nor prognosis after treatment with all-trans retinoic acid. The Leukemia Study Group of the Ministry of Health and Welfare (Kohseisho)". Leukemia, 9, 1478-1482.
25. Albitar, M., Chang, K.S., Pierce, S., Kantarjian, H. and Estey, E. (1999) "The short form of PML-RARalpha fusion transcript is associated with poor survival". Leuk. Res., 23, 89-92.
26. Zompi, S., Legrand, O., Bouscary, D., Blanc, C.M., Picard, F., Casadevall, N., et al. (2000) "Therapy-related acute myeloid leukaemia after successful therapy for acute promyelocytic leukaemia with t(15;17): a report of two cases and a review of the literature". Br. J. Haematol., 110, 610-613.
27. Au, W.Y., Lam, C.C., Ma, F.S., Man, C., Wan, T. and Kwong, Y.L. (2001) "Therapy-related myelodysplastic syndrome after eradication of acute promyelocytic leukemia: cytogenetic and molecular features". Hum. Pathol., 32, 126-129.
28. Latagliata, R., Petti, M.C., Fenn, S., Mancini, M., Spiriti, M.A., Breccia, M., et al. (2002) "Therapy-related myelodysplastic syndrome-acute myelogenous leukemia in patients treated for acute promyelocytic leukemia: an emerging problem". Blood, 99, 822-824.
29. Thomas, X., Le, Q.H. and Fiere, D. (2002) "Anthracycline-related toxicity requiring cardiac transplantation in long-term disease-free survivors with acute promyelocytic leukemia". Ann. Hematol., 81, 504-507.
30. Slack, J.L., Willman, C.L., Andersen, J.W., Li, Y.P., Viswanatha, D.S., Bloomfield, C.D., et al. (2000) "Molecular analysis and clinical outcome of adult APL patients with the type V PML-RARalpha isoform: results from intergroup protocol 0129". Blood, 95, 398-403.
31. Benedetti, L., Levin, A.A., Scicchitano, B.M., Grignani, F., Allenby, G., Diverio, D., et al. (1997) "Characterization of the retinoid binding properties of the major fusion products present in acute promyelocytic leukemia cells". Blood, 90, 1175-1185.
32. Nervi, C., Ferrara, F.F., Fanelli, M., Rippo, M.R., Tomassini, B., Ferrucci, P.F., et al. (1998) "Caspases mediate retinoic acid-induced degradation of the acute promyelocytic leukemia PML/RARalpha fusion protein". Blood, 92, 2244-2251.
33. Slack, J.L. and Yu, M. (1998) "Constitutive expression of the promyelocytic leukemia-associated oncogene PML-RARalpha in TF1 cells: isoform-specific and retinoic acid-dependent effects on growth, bcl-2 expression, and apoptosis". Blood, 91, 3347-3356.
34. Padua, R.N., Robin, M., Schlageter, M.H., West, R., Muszlak, S., Pogam, C.L., et al. (2002) "Fusion-Oncogene DNA based vaccine induces protective immunity: example of a targeted therapy in an acute promyelocytic leukemia animal model". Blood, 100, 197a.